
Giulia Serra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5748405/publications.pdf Version: 2024-02-01



CILILIA SEDDA

#	Article	IF	CITATIONS
1	Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. CNS Spectrums, 2022, 27, 236-236.	1.2	0
2	A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire. CNS Spectrums, 2022, 27, 235-235.	1.2	3
3	Suicidal behavior in juvenile bipolar disorder and major depressive disorder patients: Systematic review and meta-analysis. Journal of Affective Disorders, 2022, 311, 572-581.	4.1	15
4	Manic and Depressive Symptoms in Children Diagnosed with Noonan Syndrome. Brain Sciences, 2021, 11, 233.	2.3	3
5	Characteristics Associated with Depression Severity in 270 Juveniles in a Major Depressive Episode. Brain Sciences, 2021, 11, 440.	2.3	7
6	Parkinson's Disease Symptoms Have a Distinct Impact on Caregivers' and Patients' Stress: A Study Assessing the Consequences of the COVIDâ€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 865-867.	1.5	25
7	Suicidal behaviour and non-suicidal self-injury in children and adolescents seen at an Italian paediatric emergency department. Annali Dell'Istituto Superiore Di Sanita, 2020, 56, 303-314.	0.4	10
8	Bipolar Disorder in a Young Woman With Preexisting Rapid-Onset Dystonia-Parkinsonism and Successful Treatment With Clozapine and Lithium. Journal of Clinical Psychopharmacology, 2019, 39, 277-279.	1.4	2
9	Early clinical predictors of longâ€ŧerm morbidity in major depressive disorder. Microbial Biotechnology, 2019, 13, 999-1002.	1.7	3
10	Psychopathological features in Noonan syndrome. European Journal of Paediatric Neurology, 2018, 22, 170-177.	1.6	26
11	Early clinical predictors and correlates of long-term morbidity in bipolar disorder. European Psychiatry, 2017, 43, 35-43.	0.2	14
12	Age at menarche predicts age at onset of major affective and anxiety disorders. European Psychiatry, 2017, 39, 80-85.	0.2	16
13	Suicide Attempts in Juvenile Bipolar Versus Major Depressive Disorders: Systematic Review and Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 825-831.e3.	0.5	42
14	Factors Associated with Depression Severity in Adolescence. European Psychiatry, 2017, 41, S224-S224.	0.2	0
15	Child and Adolescent Clinical Features Preceding Adult Suicide Attempts. Archives of Suicide Research, 2017, 21, 502-518.	2.3	2
16	Pediatric Mania: The Controversy between Euphoria and Irritability. Current Neuropharmacology, 2017, 15, 386-393.	2.9	19
17	The Urgent Need of New Mood-Stabilizers: The Promising Results of Memantine. Bipolar Disorder Open Access, 2016, 1, .	0.1	0
18	Juvenile clinical predictors of clinical course and outcome in adult bipolar disorder. Lancet Psychiatry,the, 2016, 3, 307-309.	7.4	0

GIULIA SERRA

#	Article	IF	CITATIONS
19	Can unipolar and bipolar pediatric major depression be differentiated from each other? A systematic review of cross-sectional studies examining differences in unipolar and bipolar depression. Journal of Affective Disorders, 2015, 176, 1-7.	4.1	34
20	Features preceding diagnosis of bipolar versus major depressive disorders. Journal of Affective Disorders, 2015, 173, 134-142.	4.1	32
21	Can manic switches be predicted in pediatric major depression? A systematic literature review. Journal of Affective Disorders, 2015, 172, 300-306.	4.1	21
22	Three-Year, Naturalistic, Mirror-Image Assessment of Adding Memantine to the Treatment of 30 Treatment-Resistant Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2015, 76, e91-e97.	2.2	22
23	Precursors of Bipolar Disorders. Journal of Clinical Psychiatry, 2015, 76, 614-624.	2.2	68
24	The role of neuroinflammation in juvenile bipolar disorder. Neuroimmunology and Neuroinflammation, 2015, 2, 244.	1.4	3
25	Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: three case histories. Therapeutic Advances in Psychopharmacology, 2014, 4, 53-55.	2.7	11
26	Memantine in the Treatment and Prophylaxis of Bipolar II Disorder and Comorbid Fibromyalgia. Journal of Psychiatric Practice, 2014, 20, 232-236.	0.7	10
27	Clinical risk factors for bipolar disorders: A systematic review of prospective studies. Journal of Affective Disorders, 2014, 168, 314-321.	4.1	86
28	Re-examining the risk for switch from unipolar to bipolar major depressive disorder in youth with ADHD: A long term prospective longitudinal controlled study. Journal of Affective Disorders, 2014, 152-154, 347-351.	4.1	25
29	Memantine: New prospective in bipolar disorder treatment. World Journal of Psychiatry, 2014, 4, 80.	2.7	25
30	Memantine in the treatment and prophylaxis of bipolar type II mood disorder and co-morbid eating disorder: a case report. Rivista Di Psichiatria, 2014, 49, 192-4.	0.6	10
31	Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review. Journal of Affective Disorders, 2013, 148, 129-135.	4.1	186
32	Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. Journal of Neurology, 2013, 260, 3185-3187.	3.6	47
33	Antimanic and Long-Lasting Mood Stabilizing Effect of Memantine in Bipolar I Mood Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 715-717.	1.4	13
34	The Wnt Pathway in Mood Disorders. Current Neuropharmacology, 2012, 10, 239-253.	2.9	46
35	The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias. CNS Drugs, 2012, 26, 663-690.	5.9	257
36	Memantine: A New Mood Stabilizer for Treatment-Resistant Bipolar Disorders. , 2012, , .		2

GIULIA SERRA

#	Article	IF	CITATIONS
37	The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. Journal of Affective Disorders, 2012, 136, 163-166.	4.1	55
38	Antimanic and moodâ€stabilizing effect of memantine as an augmenting agent in treatmentâ€resistant bipolar disorder. Bipolar Disorders, 2010, 12, 348-349.	1.9	42
39	Patient outcome in migraine prophylaxis: the role of psychopharmacological agents. Patient Related Outcome Measures, 2010, 1, 107.	1.2	17
40	Suicidal Behavior and Alcohol Abuse. International Journal of Environmental Research and Public Health, 2010, 7, 1392-1431.	2.6	332